Discovery Laboratories Inc.
2600 Kelly Road
Suite 100
Warrington,
PA 18976-3622
United States - Map
Phone: 215-488-9300
Fax: 215-488-9301
Web Site: http://www.discoverylabs.com
| Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The companys proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. W. Thomas Amick ,
Chairman, Interim Chief Exec. Officer and Member of Strategic Partnering Committee |
$
50.00K | N/A | Mr. John G. Cooper , 50
Chief Financial Officer, Principal Accounting Officer, Exec. VP, Treasurer and Member of Management Compensation Committee |
$
307.00K |
$
0 | Dr. Robert Segal MD, FACP, 52
Chief Medical Officer and Sr. VP of Medical & Scientific Affairs |
$
290.00K |
$
0 | Mr. David L. Lopez CPA, Esq., 51
Chief Compliance Officer, Exec. VP, Gen. Counsel, Corp. Sec. and Member of Management Compensation Committee |
$
307.00K |
$
0 | Mr. Charles F. Katzer , 59
Sr. VP of Manufacturing Operations |
$
250.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.00 (0.54%) 
Profile
